Bayer AG — Sponsor Intelligence | 71 EU Trials

Filter these 71 trials by condition, phase, country and more.

Open in Search →

71 Registered trials

15 Recruiting

54 Completed trials

23 Countries active

38 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 19 Phase II: 11 Phase I/II: 1 Phase IV: 2 Phase I: 12 Phase I (Other): 22 Phase I (FiH): 3 Other: 1

Oversight events:

1 serious breach 6 temporary halts across 3 trials

View oversight register →

100%

54 of 54 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Chronic kidney disease 12 Cerebrovascular accident prophylaxis 4 Non-small cell lung cancer 4 Menopausal symptoms 3 EGFR gene mutation 3 Magnetic resonance imaging 3 Onchocerciasis 2 Atrial fibrillation 2 Helminthic infection 2 NTRK gene fusion overexpression 2 Proteinuria 2 Prostate cancer metastatic 2

Top IMPs

FINERENONE 8 ELINZANETANT 4 AFLIBERCEPT 3 ASUNDEXIAN 3 GADOQUATRANE 3 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE 2 BAY 2927088 2 BAY 3018250 2 DAROLUTAMIDE 2 LAROTRECTINIB SULFATE 2 RIOCIGUAT 2 SEVABERTINIB 2

All trials — page 2

71 total

Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended

2023-505830-89-00 Phase IV 10 countries ABIRATERONE ACETATE; ENZALUTAMIDE; PREDNISOLONE; PREDNISONE; RADIUM RA 223 DICHL…
Study to test the safety and how well patients with severe hemophilia A respond to treatment with BAY 2599023 (DTX 201), a drug therapy that… Ended

2023-505827-29-00 Phase I (FiH) 4 countries PEBOCTOCOGENE CAMAPARVOVEC
A study to test the safety and efficacy of the drug larotrectinib for the treatment of tumors with NTRK-fusion in children Ended

2022-502668-20-00 Phase I/II 9 countries LAROTRECTINIB SULFATE
Riociguat for treatment of PAH in children from 6 to less than 18 years old Ended

2023-503536-40-00 Phase III 2 countries RIOCIGUAT
A First-in-human study to learn how safe the study drug BAY2965501 is, find the best dose (single drug & combination), how it affects the bo… Ended

2023-507905-33-00 Phase I 2 countries
A first-in-human study to learn about how safe the study drug is in healthy participants Ended

2024-517512-30-00 Phase I 1 country
A study to learn about how itraconazole affects the level of emodepside in the blood when emodepside is given as a new type of tablet to hea… Ended

2024-515757-24-00 Phase I (Other) 1 country
A study to learn more about how BAY3283142 moves into, through, and out of the body of healthy participants when taken together with atazana… Ended

2024-510856-11-00 Phase I (Other) 1 country
A study in healthy men to learn about how the body absorbs, processes, and removes radioactively labeled BAY 3283142 Ended

2024-510765-42-00 Phase I (Other) 1 country
A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amo… Ended

2024-510998-26-00 Phase I 1 country
A study to learn about the blood levels of aflibercept when high-dose aflibercept is injected in both eyes of participants with diabetic mac… Ended

2024-511665-11-00 Phase IV 3 countries AFLIBERCEPT
A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni… Ended

2023-505755-40-00 Phase II 7 countries BAY 3283142
A study to learn about the safety of BAY 3283142 in people with mild to moderate high blood pressure Ended

2024-512060-58-00 Phase I (Other) 1 country
A study to learn about the amount of asundexian in the blood when healthy participants take different types of asundexian tablets Ended

2023-509447-28-00 Phase I (Other) 1 country
A study to learn how asundexian affects the amount of metformin in the blood when healthy participants take them together Ended

2023-509488-26-00 Phase I (Other) 1 country
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years Ended

2023-508447-52-00 Phase I (Other) 1 country
A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended

2023-507682-25-00 Phase II 5 countries VERICIGUAT
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet… Ended

2023-508905-26-00 Phase I (Other) 1 country
A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended

2023-504955-28-01 Phase II 7 countries ELINZANETANT
A study to learn how well the study treatment finerenone works and how safe it is in people with long-term decrease in the kidneys’ ability … Ended

2022-503024-27-00 Phase III 4 countries FINERENONE
A study to learn how BAY2927088 is taken up and handled by the body in healthy male participants Ended

2022-502771-38-00 Phase I (Other) 1 country
A study to learn more about how well BAY 3018250 works and how safe it is for people with proximal deep vein thrombosis Ended

2023-503315-15-00 Phase II 11 countries BAY 3018250
A study to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children aged 0 to less than 18 years, who … Ended

2022-501883-17-00 Phase III 6 countries GADOQUATRANE
A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended

2022-501884-41-00 Phase III 7 countries GADOQUATRANE

Showing 25–48 of 71 trials

← All sponsors A–Z